Sep 03, 2024 8:00am EDT Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September
Jul 30, 2024 8:00am EDT Processa Pharmaceuticals Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NGC-Cap in Breast Cancer
Jul 17, 2024 8:00am EDT Processa Pharmaceuticals Names Russell L. Skibsted as Chief Financial Officer
Jun 11, 2024 8:20am EDT Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
May 06, 2024 8:00am EDT Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference
Apr 30, 2024 8:00am EDT Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
Apr 11, 2024 8:00am EDT Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
Mar 28, 2024 8:15am EDT Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
